Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sutimlimab - Bioverativ

Next Previous
X
Search
Drug Profile

Sutimlimab - Bioverativ

Alternative Names: BIVV 009; Enjaymo; Sutimlimab-jome; TNT 009

Latest Information Update: 05 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iPierian
  • Developer Bioverativ; Sanofi
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autoimmune haemolytic anaemia
  • Discontinued Idiopathic thrombocytopenic purpura

Most Recent Events

  • 29 Nov 2024 Recordati completes the acquisition of the global rights to Enjaymo® from Sanofi
  • 04 Oct 2024 Sutimlimab licensed to Recordati Worldwide
  • 08 Jun 2023 Safety and efficacy data from the part B of the phase III CADENZA trial in cold agglutinin disease presented at the 28th Congress of the European Hematology Association (EHA-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top